A 54 years old male with on and off pain in abdomen, high grade fever, very low appetite, weakness, low frequency of urine and constipation. He was diagnosed to be suffering from G.I.S.T (Gastro-Intestinal Stromal cell tumor) when investigated.
Observations and Treatment :
Patient had taken conservative treatment after confirmation of diagnosis but did not find any noticeable effects.The patient was then brought to the clinic "Ayurveda".After examination; medicines were started on 25/02/2006. AMRT (Anti-malignant Rasayana treatment) was given early in the morning with honey. Other medicines like Arogyavardhini (250 mg), Tapyadi Loha (250 mg), Chandraprabha (250 mg), Kapardik bhasma (250 mg) were given thrice a day with water.
The patient showed signs of improvement. The appetite had gradually increased and energy levels had also increased.
Rasayana treatment was given in three phases (per phase of two months) for a period of six months that constitutes one cycle. The total duration of treatment was from 25/02/2006 upto 21/08/2007 that is for a period of about 16 months with three effective cycles of AMRT and investigations were done after every six months.The changes that were seen in the PET scan reports are as follows:
The changes in the tumor size:
- 4.6 x 4.5 cm large subhepatic mass lesion.19/10/2006
- There is reduction in size of sub hepatic soft tissue lesion with minimal reduction in the SUV (3.4 to 2).16/02/2007.
- No abnormal focal uptake of tracer or any mass seen in the abdomen .Rest of the scan is unremarkable and represents physiological uptake.27/06/2007.
- Difference in tumor size - 7.4 x4.5 cm.
The detailed PET scan reports datewise are as follows:
There is large subhepatic mass measuring 12x9x11 cm with heterogenous uptake of FDG. Significant uptake is seen in the periphery. There is a photogenic area inside this mass. The max SUV uptake of FDG is 3.4.Physiological uptake of the tracer is noted in the brain, both vocal cords, thymus, myocardium, liver, spleen, both renal systems, urinary bladder and gut. Rest of the whole body survey is unremarkable. There is diffused, increased uptake of tracer in the marrow. There is no baseline scan to compare with.
There is 4.6x4.5 cm large subhepatic mass lesion is seen with a small focus of FDG tracer uptake noted in the central portion of mass with maximum SUV of 3.8. Minimal tracer is seen at the gastro-jejunostomy site (4.9) suggestive of reparative change. Reactive mediastinal and abdominal lymphnodes of insignificant importance. Rest of the whole body scan is unremarkable.
Decrease in size of subhepatic mass lesion with a small focus of FDG uptake in the centre of mass suggestive of favorable response to therapy.
The study reveals impression as compared to the earlier scan, there is reduction in size of sub hepatic soft tissue lesion with minimal reduction in the SUV (3.4 to 2). There is no other abnormal focus of FDG concentration elsewhere in the body.
No abnormal focal uptake of tracer or any mass seen in the abdomen .Rest of the scan is unremarkable and represents physiological uptake.
It was observed that the AMRT (Anti-malignant Rasayana treatment) had the following advantages:
a) Symptomatic relief by reduction in pain in abdomen, fever and weakness.
b) Patient's appetite was increased with increased energy levels and without any signs of toxicity.
c) AMRT directly acts on tumor and prevents its further spread to other organs thereby decreasing the possibility of complications.
d) A remarkable change in the size of tumor was noticed after AMRT treatment.